Bioactive saponin and glycosides. III. Horse chestnut. (1): The structures, inhibitory effects on ethanol absorption, and hypoglycemic activity of escins Ia, Ib, IIa, IIb, and IIIa from the seeds of Aesculus hippocastanum L.

Chemical and Pharmaceutical Bulletin

Volumn 44, Issue 8, 1996, Pages 1454-1464

  Yoshikawa, Masayuki ^a   Murakami, Toshiyuki ^a   Matsuda, Hisashi ^a   Yamahara, Johji ^a   Murakami, Nobutoshi ^a   Kitagawa, Isao ^b  

^a KYOTO PHARMACEUTICAL UNIVERSITY   (Japan)

^b OSAKA UNIVERSITY   (Japan)

Author keywords

Aesculus hippocastanum; escin Ia; escin IIa; ethanol absorption inhibitor; horse chestnut; hypoglycemic activity

Indexed keywords

AESCULUS HIPPOCASTANUM EXTRACT; ALCOHOL; ANTIDIABETIC AGENT; ESCIN; GLUCURONIDE; GLYCOSIDE; LEAD ACETATE; SAPONIN; TRITERPENE DERIVATIVE; CENTRAL DEPRESSANT AGENT;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DECARBOXYLATION; DRUG ALCOHOL INTERACTION; DRUG POTENCY; DRUG STRUCTURE; NONHUMAN; ORAL DRUG ADMINISTRATION; ORAL GLUCOSE TOLERANCE TEST; PHOTOCHEMISTRY; PHYSICAL CHEMISTRY; PLANT SEED; RAT; STRUCTURE ACTIVITY RELATION; ANIMAL; CARBOHYDRATE ANALYSIS; CHEMISTRY; DRUG EFFECT; GLUCOSE BLOOD LEVEL; INTESTINE ABSORPTION; ISOLATION AND PURIFICATION; MEDICINAL PLANT; METABOLISM; MOLECULAR GENETICS;

ANIMALS; BLOOD GLUCOSE; CARBOHYDRATE SEQUENCE; CENTRAL NERVOUS SYSTEM DEPRESSANTS; ESCIN; ETHANOL; HYPOGLYCEMIC AGENTS; INTESTINAL ABSORPTION; MOLECULAR SEQUENCE DATA; PLANTS, MEDICINAL; RATS; SEEDS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0030209972     PISSN: 00092363     EISSN: None     Source Type: Journal    
DOI: 10.1248/cpb.44.1454     Document Type: Article

References (42)

1. Part II : Yoshikawa M., Murakami T., Matsuda H., Ueno T., Kadoya M., Yamahara J., Murakami N., Chem Pharm. Bull., 44, 1305-1313 (1996).
2. a) Rothkopf V. M., Vogel G., Arzneim. Forsch., 26, 225-235 (1976);
3. b) Annoni F., Mauri A., Marincola F., Resele L. F., ibid., 29, 672-675 (1979);
4. c) Proserpio G., Gatti S., Genesi P., Fitoterapia, 51, 113-128 (1980).
5. a) Hoppe W., Gieren A., Brodherr N., Tschesche R., Wulff G., Angew. Chem. Int. Ed. Engl., 7, 547-548 (1968);
6. b) Wulff G., Tschesche R., Tetrahedron, 25, 415-436 (1969);
7. c) Wagner J., Hoffmann H., Low I., Hoppe-Seyler's Z. Physicol. Chem., 351, 1133-1140 (1970).
8. a) Pietta P., Mauri P., Facino R. M., Carini M., J. Chromatogr., 478, 259-263 (1989);
9. b) Facino R. M., Carini M., Moneti G., Arlandini E., Pietta P., Mauri P., Org. Mass Spectrometry, 26, 989-990 (1991).
10. a) Yoshikawa M., Murakami T., Ueno T., Kadoya M., Matsuda H., Yamahara J., Murakami N., Chem. Pharm. Bull., 43, 350-352 (1995);
11. b) Yamahara J., Matsuda H., Yamaguchi S., Shimoda H., Murakami N., Yoshikawa M., Nat. Med., 49, 76-83 (1995);
12. c) Yamahara J., Miki A., Tsukamoto K., Murakami N., Yoshikawa M., ibid., 49, 84-87 (1995);
13. d) Yoshikawa M., Ueda T., Muraoka O., Aoyama H., Matsuda H., Shimoda H., Yamahara J., Murakami N., Chem. Pharm. Bull., 43, 532-534 (1995);
14. e) Yoshikawa M., Shimada H., Shimoda H., Matsuda H., Yamahara J., Murakami N., ibid., 43, 1245-1247 (1995);
15. f) Yoshikawa M., Yamaguchi S., Nishisaka H., Yamahara J., Murakami N., ibid., 43, 1462-1465 (1995);
16. g) Yamahara J., Matsuda H., Shimoda H., Wariishi N., Yagi N., Murakami N., Yoshikawa M., Folia Pharmacol. Jpn., 105, 365-379 (1995).
17. Yoshikawa M., Matsuda H., Harada E., Murakami T., Wariishi N., Yamahara J., Murakami N., Chem. Pharm. Bull., 42, 1354-1356 (1994).
18. Yoshikawa M., Harada E., Matsuda H., Murakami T., Yamahara J., Murakami N., Chem. Pharm. Bull., 41, 2069-2071 (1993).
19. Yoshikawa M., Yoshizumi S., Ueno T., Matsuda H., Murakami T., Yamahara J., Murakami N., Chem. Pharm. Bull., 43, 1878-1882 (1995).
20. Yoshikawa M., Harada E., Murakami T., Matsuda H., Yamahara J., Murakami N., Chem. Pharm. Bull, 42, 742-744 (1994).
21. a) Yoshikawa M., Murakami T., Ueno T., Kadoya M., Matsuda H., Yamahara J., Murakami N., Chem. Pharm. Bull., 43, 350-352 (1995);
22. b) Idem, ibid., 43, 2115-2122 (1995).
23. a) Yoshikawa M., Murakami T., Kadoya M., Matsuda H., Yamahara J., Muraoka O., Murakami N., Heterocycles, 41, 1621-1626 (1995);
24. b) Yoshikawa M., Murakami T., Kadoya M., Matsuda H., Muraoka O., Yamahara J., Murakami N., Chem. Pharm. Bull., 44, 1212-1217 (1996).
25. Murakami N., Murakami T., Kadoya M., Matsuda H., Yamahara J., Yoshikawa M., Chem. Pharm. Bull., 44, 469-471 (1996).
26. Yoshikawa M., Harada E., Murakami T., Matsuda H., Wariishi N., Yamahara J., Murakami N., Kitagawa I., Chem. Pharm. Bull., 42, 1357-1359 (1994).
27. Kitagawa I., Yoshikawa M., Heterocycles, 8, 783-811 (1977).
28. 13)
29. Yoshikawa K., Nakagawa M., Yamamoto R., Arihara S., Matsuura K., Chem. Pharm. Bull., 40, 1779-1782 (1992).
30. Yosioka I., Matsuda H., Imai K., Nishimura T., Kitagawa I., Chem. Pharm. Bull., 19, 1200-1213 (1971).
31. The proportions of carbohydrates were determined from the peak areas in GLC analysis.
32. a) Kitagawa I., Yoshikawa M., Imakura Y., Yosioka I., Chem. Ind. (London), 1973, 276-277;
33. b) Kitagawa I., Yoshikawa M., Yosioka I., Tetrahedron Lett., 1973, 3997-3998;
34. c) Kitagawa I., Yoshikawa M., Imakura Y., Yosioka I., Chem. Pharm. Bull., 22, 1339-1347 (1974).
35. 13C), distortionless enhancement by polarization transfer (DEPT) and HMBC experiments.
36. Kitagawa I., Kobayashi K., Yoshikawa M., Abstract of Papers, the 26th Annual Meeting of the Japanese Society of Pharmacognosy, Fukuoka, Nov. 1979, p. 21.
37. a) Kitagawa I., Yoshikawa M., Ikenishi Y., Im K. S., Yosioka I., Tetrahedron Lett., 1976, 549-552;
38. b) Kitagawa I., Yoshikawa M., Im K. S., Ikenishi Y., Chem. Pharm. Bull., 25, 657-666 (1977).
39. Usual acetylation of 6 furnished the monoacetate mixture (6a), which was subjected to preparative TLC separation to give a major component. But the stereostructure of the major component has not yet been determined (see Experimental).
40. 3)
41. Yosioka I., Nishimura T., Matsuda A., Kitagawa I., Chem. Pharm. Bull., 18, 1610-1620 (1970).
42. Williams S. C., Jones J. K. N., Can. J. Chem., 45, 275-290 (1967).